HRB enters the week after its fiscal year-end earnings print with a striking divergence at its core: short sellers have been covering aggressively through July and into August, yet the Street's consensus price target still sits below where the stock is currently trading.
The short interest story is the clearest one to tell here. Bears have meaningfully retreated over the past month — short interest has fallen 16% to 13.2% of free float, from a peak near 20.8 million shares in early July to roughly 16.7 million now. That unwind accelerated sharply after the July 23 earnings date, with shorts shedding nearly 3 million shares in a week. At 13.2% of float, the position remains elevated in absolute terms, but the direction of travel is firmly lower. Borrowing costs remain undemanding at 0.48%, and availability is loose at 435% of short interest — meaning roughly four shares are available to borrow for every one already shorted. That combination gives remaining short sellers little squeeze pressure to worry about. The ORTEX short score of 64, while still above mid-range, has edged down from 65.3 a week ago, tracking the cover-and-retreat narrative.
Options positioning offers a mild counterpoint. The put/call ratio has climbed to 0.92, a touch above its 20-day average of 0.87 and running about 1.6 standard deviations above that mean — not extreme, but trending more defensive as the stock approaches levels where the Street sees limited upside. That's still well below the 52-week high PCR of 1.43, so this is caution rather than alarm. The direction of the PCR matters: it dropped from near 0.95 in early July as shorts were covering, then drifted back up this week, suggesting some hedging demand is returning even as bears exit the direct short book.
The Street's view is where things get genuinely uncomfortable for the bull case. Barrington Research raised its target to $60 on August 12 — the same day this note was filed — maintaining its Outperform rating, a real-money endorsement of the post-earnings move. Stephens initiated at Equal-Weight with a $47 target in late July, essentially calling fair value right where the stock was trading at the time. Goldman Sachs, the loudest bear on the name, maintained its Sell with a $32 target set in February — a level the stock has now traded well through. The mean price target across the analyst universe sits at $40, against a current price of $46.67, implying the consensus is actually 14% below the market. That gap is unusual and reflects a polarised setup: Barrington is effectively the lone bull at $60, Goldman is anchoring the bear camp at $32, and the new Stephens initiation at $47 lands closest to where the stock sits. On valuation, the EV/EBITDA of 6.4x has expanded by 0.2x turns over the past month as the price rallied, while the P/E near 7x remains historically modest. The EPS surprise factor score ranks at the 79th percentile, and the ev/ebit score hits the 89th — both confirming the stock screens cheap relative to earnings and asset quality.
The fundamental tension behind all this positioning is the guidance gap the company flagged with its Q4 beat. Revenue grew 4.6% to $1.11 billion and operating income rose 5.8%, both ahead of estimates — but management guided FY26 adjusted EPS to $4.85–$5.00, below the $5.15 consensus, citing a higher-than-expected tax rate of 25% versus 22% in the prior year. That single factor — worth roughly $0.19 per share — is what has kept the mean price target anchored below the current price even as the stock ripped 17.9% over the past month. Insider activity is quiet and offers no directional signal; the only trades within the past 90 days are a handful of token sales by a divisional president worth under $40,000 combined. Peers across the correlated basket — LOPE, STRA, and COUR — all fell 4–7% on the week, making HRB's 1.3% gain stand out as notably resilient post-results.
The next earnings event is not until November 3, leaving three months before the next hard catalyst. What to watch in the interim is whether the analyst consensus begins to migrate toward the stock's new price level — particularly whether Goldman revisits its $32 Sell following the earnings beat — and whether short interest continues its steady grind lower or finds a floor as the stock trades at a premium to most targets.
See the live data behind this article on ORTEX.
Open HRB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
